Treatment of Multiple Sclerosis with Copolymer I

  • Murray B. Bornstein
  • Kenneth P. Johnson
Part of the Clinical Medicine and the Nervous System book series (CLIN.MED.NERV.)


The most desirable treatment for multiple sclerosis (MS) would safely arrest the disease process before clinical signs and symptoms had appeared. This has not yet been achieved. Failing this, one would wish safely to arrest or reverse its course as soon as possible after its earliest clinical manifestations. This chapter will present the results of two pilot trials of a synthetic product, Copolymer I (Cop 1), which show promise of attaining the second objective.


Multiple Sclerosis Multiple Sclerosis Patient Myelin Basic Protein Expand Disability Status Scale Experimental Allergic Encephalomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abramsky O, Teitelbaum D, Arnon R (1977) Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and acute disseminated encephalomyelitis: Preliminary report. J Neurol Sci 31: 433–438PubMedCrossRefGoogle Scholar
  2. Anderson S, Auguier A, Hauck W et al. (1980) Statistical methods for comparative studies. John Wiley and Sons, USA, pp 199–214Google Scholar
  3. Appel SH, Bornstein MB, Seegal BC, Murray MR (1962) The application of tissue culture to the study of experimental “allergic” encephalomyelitis. II. Immunological observations. Proc Int Cong Neuropath 2: 283Google Scholar
  4. Arnon R (1981) Experimental allergic encephalomyelitis — susceptibility and suppression. Immunol Rev 55: 5–30PubMedCrossRefGoogle Scholar
  5. Arnon R, Teitelbaum D (1980) Desensitization of experimental allergic encephalomyelitis with synthetic peptide analogues. In: Davison AN, Cuzner ML (eds) The suppression of experimental allergic encepahlomyelitis and multiple sclerosis. Academic Press, New York, pp 105–117Google Scholar
  6. Barsumian EL, Isersky C, Petrino MG et al. (1981) IgE-induced histamine release from rat basophilic leukemia cell lines: Isolation of releasing and nonreleasing clones. Eur J Immunol 11: 317–323PubMedCrossRefGoogle Scholar
  7. Bornstein MB (1963) A tissue culture approach to demyelinative disorders. Nat Cancer Inst Monogr 11: 197–214PubMedGoogle Scholar
  8. Bornstein MB (1973) The immunopathology of demyelinating disorders examined in organotypic cultures of mammalian central nerve tissue. In: HM Zimmerman (ed) Progress in neuropathology, vol 2. Grune and Stratton, New York, pp 69–90Google Scholar
  9. Bornstein MB, Appel SH (1961) The application of tissue culture to the study of experimental “allergic” encephalomyelitis. I. Patterns of demyelination. J Neuropath Exp Neurol 20: 141–157CrossRefGoogle Scholar
  10. Bornstein MB, Raine CS (1976) The initial structural lesion in serum-induced demyelination in vitro. Lab Invest 35: 391–401PubMedGoogle Scholar
  11. Bornstein MB, Raine CS (1977) Multiple sclerosis and experimental allergic encephalomyelitis. Specific demyelination of CNS in culture. Neuropathology Applied Neurobiology 3: 359–367CrossRefGoogle Scholar
  12. Bornstein MB, Miller A, Slagle S et al. (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317: 408–414PubMedCrossRefGoogle Scholar
  13. Bornstein MB, Miller A, Slagle S et al. (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive-multiple sclerosis. Neurology 41: 533–539PubMedGoogle Scholar
  14. Hauser L, Dawson DM, Lehrich JR et al. (1983) Intense immunosuppression in progressive multiple sclerosis. N Engl J Med 308: 173–180PubMedCrossRefGoogle Scholar
  15. Keith AB, Arnon R, Teitelbaum D et al. (1979) The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J Neurol Sci 42: 267–274PubMedCrossRefGoogle Scholar
  16. Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33: 1444–1452PubMedGoogle Scholar
  17. Lando Z, Teitelbaum D, Arnon R (1979) Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol 123: 2156–2160PubMedGoogle Scholar
  18. Paterson PY (1977) Autoimmune neurologic disease: Experimental animal systems and implications for multiple sclerosis. In: Talmage N (ed) Autoimmunity: Genetic, immunologic, virologic and clinical aspects. Academic Press, New York, pp 643–692Google Scholar
  19. Paterson PY (1978) The demyelinating diseases: Clinical and experimental studies in animals and man. In: Samter M, Alexander N, Rose B, Sherman WB, Talmage DW, Vaughn JH (eds) Immunologic diseases, 3rd edn. Little, Brown and Company, Boston, pp 1400–1435Google Scholar
  20. Paterson PY (1979) Neurological disorders. In: WJ Irvine (ed) Medical immunology. Teviot Scientific Publications, Edinburgh, pp 361–381Google Scholar
  21. Paterson PY (1980) The immunopathology of experimental allergic encephalomyelitis. In: Davison AN, Cuzner MC (eds) The suppression of experimental allergic encephalomyelitis in multiple sclerosis. Academic Press, New York, pp 11–30Google Scholar
  22. Poser CM, Patty DW, Scheinberg L et al. (1983) New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 13: 227–231PubMedCrossRefGoogle Scholar
  23. Raine CS, Bornstein MB (1970) Experimental allergic encephalomyelitis. A light and electron microscope study of remyelination and “sclerosis” in vitro. J Neuropath Exp Neurol 29: 552–574Google Scholar
  24. Raine CS, Bornstein MB (1979) Experimental allergic neuritis ultrastructure of serum-induced myelin aberrations in PNS cultures. Lab Invest 40: 423–432PubMedGoogle Scholar
  25. Teitelbaum D, Meshorer A, Hirshfeld T et al. (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1: 242–248PubMedCrossRefGoogle Scholar
  26. Teitelbaum D, Webb C, Meshorer A et al. (1973) Suppression by synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol 3: 273–279PubMedCrossRefGoogle Scholar
  27. Teitelbaum D, Webb C, Bree M et al. (1974) Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol 3: 256–262PubMedCrossRefGoogle Scholar
  28. Webb C, Teitelbaum D, Arnon R et al. (1973) In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol 3: 279–286PubMedCrossRefGoogle Scholar
  29. Webb C, Teitelbaum D, Herz A et al. (1976) Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunochemistry 13: 333–337PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1992

Authors and Affiliations

  • Murray B. Bornstein
  • Kenneth P. Johnson

There are no affiliations available

Personalised recommendations